Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Lorin Jeffry Randall to its board and chairman of the audit committee.
Mr. Randall has over 30 years of experience serving in financial and operating roles spanning biotechnology, pharmaceuticals and manufacturing. He has led a number of companies through multimillion-dollar financings, and mergers and acquisitions.
He currently serves on the boards of Athersys, where he serves as chairman of the audit and compensation committees, and Acorda Therapeutics, where he serves on the audit, compliance and nominations, and governance committees.
“We’re at a critical inflection point for the company, and having Jeff’s expertise on the board and serving as chairman of the audit committee will be extremely valuable as we work to advance voclosporin to market,” Charles Rowland, CEO of Aurinia, said in a statement.